Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CFO Sells $37,649.64 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CFO Brian Piekos sold 1,862 shares of KalVista Pharmaceuticals stock in a transaction on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $37,649.64. Following the completion of the sale, the chief financial officer directly owned 18,150 shares of the company’s stock, valued at approximately $366,993. This represents a 9.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Piekos also recently made the following trade(s):

• On Monday, February 23rd, Brian Piekos sold 1,767 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $15.57, for a total value of $27,512.19.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $19.56 on Thursday. The company has a market cap of $1.00 billion, a P/E ratio of -4.95 and a beta of -0.40. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 52 week low of $9.83 and a 52 week high of $21.31. The business has a fifty day simple moving average of $17.67 and a 200-day simple moving average of $15.31.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its position in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of KalVista Pharmaceuticals in the third quarter worth about $55,000. Wolverine Asset Management LLC purchased a new stake in shares of KalVista Pharmaceuticals in the third quarter worth about $57,000. KLP Kapitalforvaltning AS purchased a new stake in shares of KalVista Pharmaceuticals in the third quarter worth about $63,000. Finally, Truvestments Capital LLC boosted its position in shares of KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 3,360 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. HC Wainwright boosted their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Wall Street Zen downgraded KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Stifel Nicolaus boosted their price target on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Finally, Needham & Company LLC boosted their price target on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, KalVista Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.